The companies will use clinical trial plasma samples and data to drive the AthosOmics.AI platform to identify efficacy biomarkers for Xeptiva's lead experimental therapeutic vaccine for canine ...
UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM ESTCompany ParticipantsMaxwell Krakowiak - Senior VP ...
Najar, the expert in SaaS investment management and optimization for enterprises, reports strong adoption of its procurement solutions and presents its strategic roadmap to support its European ...
Silicon Valley startups are pushing the boundaries of reproductive genetics, hoping to prevent diseases as well as improve chances for a high IQ ...
The world needs more food, and traditional farming isn’t always cutting it anymore. Weather’s gotten weird, and ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.
4don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged
Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. (NASDAQ:TSLA), Pony AI Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback